Virtus Investment Advisers’s MoonLake Immunotherapeutics MLTX Stock Holding History

Virtus Investment Advisers’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$341K	Sell	17,507 -929	-5%	-$16.8K	0.08%	353
2026 Q1	$344K	Buy	18,436 +449	+2%	+$7.44K	0.09%	260
2025 Q4	$237K	Buy	17,987 +15,402	+596%	+$182K	0.06%	351
2025 Q3	$18.5K	Buy	2,585 +449	+21%	+$23.4K	0.01%	439
2025 Q2	$101K	Sell	2,136 -914	-30%	-$37.2K	0.03%	330
2025 Q1	$119K	Buy	+3,050	New	+$131K	0.03%	393

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtus Investment Advisers's MLTX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its MoonLake Immunotherapeutics (MLTX) stake by 5% in Q2 2026, selling an estimated $16.8K and leaving 17,507 shares worth $341K. The position accounts for 0.08% of the portfolio, ranked #353.

Virtus Investment Advisers first reported a position in MLTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $344K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Virtus Investment Advisers held 17,507 shares of MoonLake Immunotherapeutics worth $341K as of Q2 2026.
Virtus Investment Advisers sold 929 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $16.8K.
MoonLake Immunotherapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #353 holding.
Virtus Investment Advisers first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 6 quarters since.
Virtus Investment Advisers's MoonLake Immunotherapeutics position peaked at $344K in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.